Press Releases

YEAR
Toggle Summary Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Poster sessions to highlight pooled results from the pivotal LEAP 1 and LEAP 2 Phase 3 clinical trials DUBLIN, Ireland , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association
Nabriva publication of Phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with community-acquired bacterial pneumonia (CABP)   DUBLIN, Ireland , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc
View HTML
Toggle Summary Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019
DUBLIN, Ireland , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that data from its XENLETA™ (lefamulin) and
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive
View HTML
Toggle Summary Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.
First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship DUBLIN, Ireland , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Nabriva has
View HTML
Toggle Summary Nabriva Therapeutics to Present Data at ASM/ESCMID Conference Demonstrating Utility of Xenleta™ (lefamulin) for Patients with Community-Acquired Bacterial Pneumonia (CABP)
DUBLIN, Ireland , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will present data at the ASM/ESCMID
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com